Knowing which variants induce hypo- or hyperfunctional protein activity can guide treatment decisions; for example, knowing the functional impact of a variant in BRCA1 can impact the level of pre-cancer surveillance or prophylactic surgeries and may affect cancer care decisions such as including DNA-damaging agents or PARP inhibitors in the treatment regimen [1]. This evidence concerns the gene BRCA1 and cancer.